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ABSTRACT Objective: To determine the occurrence of neuropsychiatric symptomatology and the rela-
tion to future development of Alzheimer disease (AD) in persons with and without mild cognitive im-
pairment (MCI). Method: We followed 185 persons with no cognitive impairment and 47 with MCI
(amnestic and multidomain), ages 75 to 95, from the population-based Kungsholmen Project, Stock-
holm, Sweden, for 3 years. Three types of neuropsychiatric symptoms were assessed at baseline:
mood-related depressive symptoms, motivation-related depressive symptoms, and anxiety-related
symptomatology. AD at 3-year follow-up was diagnosed according to Diagnostic and Statistical Man-
ual for Mental Disorders-III-R criteria. Results: Psychiatric symptoms occurred more frequently in per-
sons with MCI (36.2% mood, 36.2% motivation, and 46.8% anxiety symptoms) than in cognitively
intact elderly individuals (18.4% mood, 13.0% motivation, and 24.9% anxiety). Of persons with both
MCI and anxiety symptoms, 83.3% developed AD over follow-up vs 6.1% of cognitively intact per-
sons and 40.9% persons who had MCI without anxiety. Among persons with MCI, the 3-year risk of
progressing to AD almost doubled with each anxiety symptom (relative risk [RR] 1.8 [1.2 to 2.7] per
symptom). Conversely, among cognitively intact subjects, only symptoms of depressive mood were
related to AD development (RR1.9 [1.0 to 3.6] per symptom).Conclusions: The predictive validity of
mild cognitive impairment (MCI) for identifying future Alzheimer disease (AD) cases is improved in the
presence of anxiety symptoms. Mood-related depressive symptoms (dysphoria, suicidal ideation, etc.)
in preclinical AD might be related to the neuropathologic mechanism, as they appear preclinically in
persons both with and without MCI. NEUROLOGY 2007;68:1596–1602
Mild cognitive impairment (MCI) is a syndrome characterized by subjective and objective
cognitive impairment in the absence of dementia.1 MCI subclassifications include an amnes-
tic form, characterized by isolated memory impairments, and one with multiple cognitive
deficits.2 Although it is documented that persons with MCI have an increased risk of Alzhei-
mer disease (AD),1,3-6 population-based studies have shown that only one-third develop de-
mentia, whereas others improve, reverting to a normal level of cognitive functioning,5-6 and
some die,5,7 suggesting multiple etiologies for MCI.8
Neuropsychiatric disturbances are common in MCI, with a prevalence between 43 and
59%,9-13 and the same symptoms frequently occur even in the early phases of AD,14-17 particu-
larly depression. In addition, depression is related to reduced cognitive performance in non-
demented elderly individuals18-21 and has been suggested as a risk factor for incident MCI.8,22
It remains unclear whether neuropsychiatric disturbances represent independent causes of
MCI, symptoms related to an already ongoing neurodegenerative process, or a reaction to
cognitive deterioration. Two clinical studies reported contradictory results concerning the
role of depressive symptoms in the progression of MCI to AD.23,24
To examine the possible role of neuropsychiatric disturbances in MCI, we investigated
mood- and motivation-related depressive symptoms as well as anxiety symptomatology in
persons withMCI in a longitudinal population-based study. Specific aims include 1) investigating
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the frequency of neuropsychiatric symptom-
atology in MCI; 2) assessing the contribution
of anxiety and depressive symptomatology in
progression fromMCI to AD over 3 years; and
3) examining whether neuropsychiatric distur-
bances predict AD in persons withoutMCI.
METHODS Study population. Participants were taken
from the Kungsholmen Project, a longitudinal population-
based study initiated in 1987 to assess the occurrence, risk fac-
tors, and evolution of dementia in individuals aged 75 years
living in the Kungsholmen area of Stockholm, Sweden. A two-
phase study design was conducted at baseline. First the cogni-
tive status of the 1,810 subjects was assessed by trained nurses
using the Mini-Mental State Examination (MMSE),25 and a
sample of 668 individuals underwent a thorough clinical assess-
ment, including both a psychiatric and a neurologic examina-
tion by a physician and comprehensive neuropsychological
testing. Full description of the study design and data collection
has been previously described.26,27 In brief, all persons scoring
less than or equal to 24 on the MMSE and a sample of age- and
sex-matched control subjects scoring more than 24 points were
selected for the clinical examination.
For the current study, we used the clinical sample of 668
persons. Of them, 225 were excluded due to dementia diag-
nosed by a physician according to Diagnostic and Statistical
Manual of Mental Disorders (DSM) III-R criteria as described
in detail later.26,27 To obtain accurate age- and education-
specific normative values for cognitive functioning, 40 persons
were excluded due to MMSE20, unknown educational level,
or age over 95 years. Of the remaining persons, 296 underwent
comprehensive and complete neuropsychological assessment.
Sixty-four persons did not fulfill the criteria for amnestic or mul-
tidomain MCI, but they also did not perform at a normal level of
cognitive functioning; namely, they had significant impairments (1
SDbelowage- and education-adjusted norms)4 on theMMSE (n
24, 8.1%) or isolated impairment in tasks of visuospatial or lan-
guage functioning (n  40, 13.5%). Thus, 47 persons with MCI
(amnestic or multidomains) and 185 persons with normal cogni-
tive functioning at baseline constituted the study population.
Baseline characteristics. Information on age, education,
and sex was collected at baseline. Education was calculated as
the maximum level achieved and dichotomized into low (8
years) and high (8 years).
Psychiatric examination. Symptoms of depression and anx-
iety were assessed during examination by a geriatric psychia-
trist using the Comprehensive Psychopathological Rating Scale
(CPRS).28 The presence and severity of each symptom were re-
ported by the participant and were rated by the psychiatrist on
a six-point scale, with a score of 2 to 6 indicating presence of a
severe symptom. Based on previous research,14 we used the
findings of principal component analyses on the CPRS to iden-
tify symptoms reflecting mood- or motivation-related symp-
tomatology. The mood group included dysphoria, suicidal
ideation/thoughts of death, feelings of guilt, and appetite dis-
turbance. The motivation grouping included lack of interest,
concentration difficulties, psychomotor disturbances, and loss
of energy. Anxiety symptoms included indecision, persistent
worrying, anxiety, and social withdrawal.
Subjective memory complaints. At baseline, nurses admin-
istered a questionnaire to close informants to detect possiblemem-
ory decline of the relative. All participants were asked about
memory problems both in the nurse interview and during the psy-
chiatric examination. Presence of a memory complaint was de-
fined as a report of problems by either the subject in the nurse
interview or psychiatric examination or a report by the informant.
Neuropsychological testing. Cognitive functioning was as-
sessed at baseline by neuropsychologists using an extensive cog-
nitive battery, as described in detail previously.20 Three specific
cognitive domains were the focus of the current study: episodic
memory, language fluency, and visuospatial functioning. Im-
pairment was defined as scoring less than 1 SD below the age-
and education-specific mean on the respective tests, based on
previous studies.4,5 In brief, episodic memory included a com-
posite score of four word recall tasks: free recall of rapidly pre-
sented random words, free recall of slowly presented random
words, free recall of organizable words, and cued recall of or-
ganizable words. For language, a test of verbal fluency was used
where subjects were asked to produce as many grocery items as
they could within a 60-second period. Visuospatial functioning
was evaluated using a composite score of three tests: block de-
sign, clock-setting, and clock-reading.
Criteria for baseline MCI. MCI-amnestic and MCI-
multidomains were identified based on previous proposals.2,29
The definition for both MCI subtypes required 1) subjective
memory complaints, 2) no dementia diagnosis, 3) activities of
daily living intact or functional impairment not due to cognitive
impairment (all subjects underwent a complete neurologic and
medical examination by a specialist who excluded that any
functional impairment present was not due to memory or cog-
nitive impairments), and 4) objective evidence of cognitive im-
pairment. For MCI-amnestic, objective cognitive impairments
included impairment in episodic memory task but normal func-
tioning on visuospatial and language tasks. For MCI-
multidomains, impairment was required in two or more of the
episodic memory, language, and visuospatial domains.
Diagnosis of AD. Subjects were reassessed 3.4 years (SD 0.6)
after baseline. Nineteen (8.2%) subjects did not wish to be re-
evaluated or had moved during follow-up. Thirty-three persons
(14.2%) died before examination, and their death certificates
and medical records were sought. After clinical examination of
all subjects, dementia was diagnosed according to DSM-III-R
criteria using a three-step procedure26-27 and made blind to base-
line characteristics. Diagnosis of AD was similar to National
Institute of Neurological and Communication Disorders and
Stroke/Alzheimer’s Disease and Related Disorders Associa-
tion30 and required gradual onset, progressive deterioration,
and lack of any other specific cause of dementia. A preliminary
diagnosis was made by the examining physician and indepen-
dently reviewed by a specialist. In the case of agreement, the
diagnosis was accepted; otherwise, a third specialist made a
final diagnosis. Dementia diagnoses for deceased subjects were
made from extensive review of medical records and death cer-
tificates using the same multiple diagnostic procedure. In the
current study, progression only to dementia of the Alzheimer
type was considered.
Data analyses. First, the frequency of neuropsychiatric symp-
tomatology in each MCI group was assessed. Logistic regres-
sion models and 2 tests were used to assess differences in the
number of neuropsychiatric symptoms between persons with
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MCI and those without cognitive impairments, adjusting for
age, sex, and education.
Second, we examined whether the baseline presence of neu-
ropsychiatric symptoms predicted progression to AD over 3
years in subjects with MCI (amnestic or multidomains). Rela-
tive risks (RRs) with 95%CI were estimated from hazard ratios
computed with Cox proportional hazard models adjusted for
age, sex, and education. The onset of AD was assumed as being
halfway between the baseline and follow-up examination or the
baseline interview and date of death. Finally, Cox models were
also used to examine whether the presence of psychiatric symp-
toms at baseline predicted development of AD in cognitively
intact persons. All analyses were also conducted using logistic
regression models including adjustments for time of follow-up
as well as diagnosis of major depression, and the results re-
mained unchanged (data not shown).
Ethical considerations. Informed consent was provided at
baseline by all participants. All parts of the Kungsholmen
Project have been approved by the Ethical Committee of the
Karolinska Institutet.
RESULTS The mean age of the study population
was 84.0 years (SD  5.1), 84.9% (n  197) of per-
sons were female, and 39.2% (n  91) had high ed-
ucation. At baseline, 185 persons had normal
cognitive functioning on all tasks, 17 persons had
MCI-amnestic, and 30 had MCI-multidomains. Al-
most all of the MCI-multidomains category were
characterized by episodic memory impairment.
The figure shows the distribution of persons
with at least one neuropsychiatric symptom in each
of the three categories (anxiety and mood- or
motivation-related depressive symptoms), for per-
sons with and without MCI at baseline. Logistic re-
gression analyses were conducted to assess whether
the odds of exhibiting neuropsychiatric symptom-
atology was higher among persons with MCI vs
those without cognitive impairment for each of the
three symptomatic groups (table 1). Persons with
MCI-amnestic were four times more likely to have
at least one clinically severe psychiatric symptom vs
persons without cognitive impairments, and a simi-
lar result was seen for MCI-multidomains.
Persons with MCI-amnestic were almost four
times more likely to have at least one motivation-
related symptom than persons without cognitive
impairment. Specifically, lack of interest was severe
in 17.6% of persons with MCI-amnestic compared
with 0.5% of persons without impairment (p 
0.000), and concentration difficulties were also
more common (17.6 vs 4.9%, p  0.033). Although
the group of mood symptoms was not different be-
tween MCI-amnestic and no cognitive impairment,
one symptom, suicidal ideation, was more frequent
in MCI-amnestic (17.6 vs 3.2%, p  0.006). Social
withdrawal, from the anxiety category, was more
often present in MCI-amnestic compared with cog-
nitively intact subjects (17.6 vs 4.3%, p 0.021).
In all three categories, persons with MCI-
multidomains were more likely to have at least one
symptom than cognitively intact subjects. The fol-
lowing specific symptoms were independently ele-
Figure Proportion of persons with baseline neuropsychiatric symptoms according
to cognitive status
Table 1 Proportion of persons who had clinically severe psychiatric symptoms at baseline
At least one clinically severe symptom of four symptoms for each category
At least one clinically severe
symptom of 12 symptoms
Mood Motivation Anxiety All three symptomatic groups
Baseline cognitive
status % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI
No cognitive
impairment,
n 185
18.4 1.0 13.0 1.0 24.9 1.0 38.9 1.0
MCI all types,
n 47
36.2 2.5 1.2–5.0 36.2 3.8 1.8–8.0 46.8 2.5 1.3–5.2 66.0 4.5 2.0–9.8
MCI-amnestic,
n 17
35.3 2.3 0.8–6.8 35.3 3.9 1.3–11.9 41.2 2.1 0.7–6.0 64.7 4.0 1.2–13.8
MCI-multidomains,
n 30
36.7 2.5 1.1–5.7 36.7 3.8 1.6–9.0 50.0 2.9 1.3–6.7 66.7 4.9 1.9–12.7
Odds ratio (ORs) for presence of psychiatric symptoms in persons with different types of mild cognitive impairment (MCI) com-
pared with persons without cognitive impairment, calculated with logistic regression analysis adjusted for age and sex.
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vated in persons with MCI-multidomains:
depressed mood and feelings of guilt (26.7 vs 9.2%,
p 0.006); suicidal ideation/thoughts of death (16.7
vs 3.2%, p  0.002); lack of interest (23.3 vs 0.5%,
p 0.000); psychomotor disturbances (6.7 vs 1.1%,
p  0.036); persistent worrying (26.7 vs 8.1%, p 
0.002); and social withdrawal (20.0 vs 4.3%, p 
0.001).
Table 2 shows the follow-up vital and cognitive
status of subjects with or without baselineMCI who
participated at 3-year follow-up or died during the
period (19 persons refused or moved during follow-
up). Over half of the persons with MCI-amnestic or
MCI-multidomains developed AD over 3 years
compared with 5.9% of persons without baseline
cognitive impairments. Ten persons received a diag-
nosis of another dementia type, but these were ex-
cluded from the follow-up analyses to focus
specifically on dementia of the Alzheimer type.
MCI-amnestic and MCI-multidomains were
merged together for further analyses, as almost all
persons with MCI-multidomains had episodic
memory impairments, MCI-amnestic and MCI-
multidomains had similar progression rate to AD,
and the pattern of neuropsychiatric symptomatol-
ogy was comparable. First, we investigated whether
the presence of neuropsychiatric symptomatology
predicted progression to AD over 3 years among
persons with MCI. Mood-related depressive symp-
toms at baseline were high both in persons with
MCI who remained dementia-free (31.3%) and in
persons with MCI who developed AD (37.5%) and
thus there was no statistically increased risk of de-
veloping AD in persons with MCI plus depressive
symptoms (table 3). However, anxiety symptom-
atology predicted AD in subjects with MCI. For
each increasing number of anxiety symptoms, the
risk of AD almost doubled (RR: 1.8, 95% CI: 1.2 to
2.7). After further adjustment for baseline cognitive
status, the results remained unchanged (RR: 1.9,
95% CI: 1.2 to 2.8). Each anxiety symptom was ex-
amined individually. Persons with MCI who re-
ported problems with decision making had a
fivefold risk of AD vs MCI subjects with no such
problems (RR: 5.6, 95% CI: 1.1 to 29.0), and those
with persistent worrying also had a fivefold in-
creased risk (RR: 5.3, 95% CI: 1.8 to15.6).
Second, we conducted an additional analysis to
calculate the risk of AD in persons with MCI with
and without anxiety compared with cognitively in-
tact elderly individuals. Compared with 6% of the
cognitive normal elderly individuals, 40.9% of per-
Table 2 Follow-up status according to baseline cognitive status: proportion of persons with or without MCI who
progressed to dementia after 3 years
Baseline cognitive status
No cognitive impairment MCI-amnestic and -multidomains
Status at 3-y follow-up* n % n %
Alive, without dementia 131 77.1 8 18.6
Dead, without dementia 22 12.9 8 18.6
Alzheimer disease 10 5.9 24 56.2
Other dementias 7 4.1 3 7.0
*Nineteen persons refused to participate or had moved at follow-up examination.
MCImild cognitive impairment.
Table 3 Mood-related and motivation-related depressive symptoms and anxiety symptoms in relation to progression
to AD in persons with MCI (amnestic or multidomains) and persons with no cognitive impairment: RR for
AD per increasing number of clinically severe psychiatric symptoms
MCI-amnestic or -multidomains,
n 47
No cognitive impairment,
n 185
Presence of clinically severe
symptoms as predictors of AD RR 95% CI for AD RR 95% CI for AD
Mood symptoms: 0–4 symptoms 0.9 0.6–1.5 1.9 1.0–3.6
Motivation-related symptoms: 0–4
symptoms
1.1 0.7–1.8 1.9 0.5–7.4
Anxiety symptoms: 0–4 symptoms 1.8 1.2–2.7 1.1 0.5–2.3
Relative risks (RRs) estimated from hazard ratios calculated with Cox proportional hazard models adjusted for age, sex, and
education.
AD Alzheimer disease; MCImild cognitive impairment.
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sons with MCI without anxiety progressed to AD
after 3 years, whereas the progression rate to AD for
persons with MCI plus anxiety was 83.3%. This
corresponded to a 10-fold higher risk of developing
AD among MCI without anxiety (RR: 10.6, 95%
CI: 4.2 to 26.8), but a 30 times higher risk among
persons with MCI with anxiety (RR: 34.4, 95% CI:
13.9 to 85.8) than cognitively intact persons, after
adjustment for age, sex, and education.
We also examined whether the presence of neu-
ropsychiatric symptomatology in persons without
cognitive impairment predicted AD (table 3). The
risk of AD almost doubled with each increasing
number of mood-related depressive symptoms in
cognitively intact subjects.
DISCUSSION In this population-based study, neu-
ropsychiatric symptoms were common in persons
withMCI. Compared with cognitively intact elderly
persons, persons with MCI-multidomains and
MCI-amnestic were more likely to have both
depression- and anxiety-related symptomatology.
Persons with MCI plus anxiety symptomatology
had an increased risk of progressing to AD over 3
years compared with persons with MCI without
anxiety problems. Furthermore, depressed mood
was predictive of AD in persons with normal levels
of baseline cognition as well as being frequent in
persons with MCI. Together, these findings suggest
that anxiety symptoms in MCI may be a response to
the initial phases of cognitive deterioration in neu-
rodegeneration, whereas mood-related depressive
symptoms may be a preclinical sign of AD related to
the neuropathologic mechanism, present even in
persons with prodromal ADwho have no detectable
cognitive impairment.
The results support previous research showing
that neuropsychiatric symptoms are prevalent in
persons with MCI.9-11 Consistent with correspond-
ing figures between 47 and 59%, about two-thirds
of persons with MCI-amnestic and MCI-
multidomains had at least one severe neuropsychi-
atric symptom. Furthermore, symptoms were most
frequent in persons with multiple cognitive impair-
ments, mirroring previous findings8 that neuropsy-
chiatric symptoms in MCI are associated with more
severe levels of cognitive impairment. Alternative
explanations are discussed later.
Owing to the longitudinal design of our project,
we were able to follow persons with MCI to see
whether neuropsychiatric symptoms predicted pro-
gression to AD. Indeed, anxiety-related symptom-
atology was predictive of impending AD in persons
with MCI, with an almost twofold increased risk
per additional symptom. Specifically, problems
with decision making and persistent worrying had
high predictivity. The associations remained signifi-
cant even after adjusting for baseline level of cogni-
tive functioning. Adding anxiety symptoms resulted
in higher prediction than simply comparing MCI vs
no MCI. Another study on persons with question-
able dementia31 found that those who developed AD
over 3 years had more symptoms of personality
change, such as agitation, than those who did not
develop the disease.
These findings raise the question of whether such
symptoms reflect specific neuropathologic changes
in the brain or indicate a subjective reaction to the
cognitive changes. Anxiety is common in the later
stages of AD,32,33 and some evidence suggests a
pathologic mechanism underlying such distur-
bances. For example, AD patients with agitation
have greater neurofibrillary tangle burden in the or-
bitofrontal cortex.34 Our finding that milder symp-
toms of anxiety are present in the prodromal phase
could suggest that these particular pathologic mech-
anisms underlying AD might begin working early in
the course of the disease, before current diagnostic
criteria for AD are met. However, if anxiety is re-
lated to pathologic degeneration, we would expect
to see these symptoms occurring in all preclinical
AD including AD patients who are cognitively in-
tact 3 years before diagnosis, but that was not the
case. The symptomatology in preclinical AD dif-
fered depending on whether cognitive impairments
were present. In the absence of cognitive impair-
ment, depressive symptoms were elevated in pre-
clinical AD, but in conjunction with memory or
multiple cognitive disturbances, anxiety was the
predominantly predictive feature. Anxiety can be
caused by the awareness of memory loss and cogni-
tive disturbances, but not in all cases, as we found
that anxiety was not always present in persons with
MCI. It is also plausible that there is a group of
persons in the preclinical phase of AD who exhibit
anxiety symptoms and progress to clinical AD at a
faster rate.
Mood-related depressive symptoms were predic-
tive of future AD in persons without cognitive im-
pairment; the risk of AD almost doubled with each
additional symptom. Previous studies have shown
that depression is a risk factor for AD, especially
when symptoms first occur 1 year before AD diag-
nosis,35 and a neuropathologic study found more
pronounced neuropathologic changes in the hip-
pocampus in persons with concurrent depression at
time of AD diagnosis.36 Furthermore, one study23
showed that patients with bothMCI and depression
had a higher risk of developing AD than those with
MCI alone. Together, these findings suggest that
1600 Neurology 68 May 8, 2007
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depressive symptomatology could be a precursor, or
early symptom, of AD. In the current study, depres-
sive symptoms did not show a statistically signifi-
cant prediction for AD among persons with MCI
because depressive symptoms were high both in per-
sons with MCI who remained dementia-free
(31.3%) and in persons with MCI who developed
AD (37.5%). It is plausible that in the first group of
subjects, MCI was related to an underlying psychi-
atric disorder, and in the second group, MCI and
depression were associated with neurodegeneration.
The presence of preclinical depressive symptoms in
many cases of AD, including persons with or with-
out MCI, highlights the need to further investigate
the role of depression in early AD, also in the ab-
sence of clear cognitive disturbances. Further, con-
sidering that some individuals do not progress to
AD through a clinically identifiable syndrome of
cognitive impairment,4,37 it is valuable to have other
predictors that might help identify subjects at risk
who would otherwise be undetected.
Some limitations deserve mention. First, because
the data derive from a large population-based study,
MCI was defined according to performance on neu-
ropsychological tests and self-reported symptoms,
rather than based on a clinical diagnosis. However,
as our findings indicate that neuropsychiatric symp-
toms might be helpful in predicting the prognosis of
MCI patients, they should be replicated within clin-
ical populations. Second, the relatively small sample
may have led to an underestimation of the impact of
neuropsychiatric symptomatology in predicting
AD. Symptoms such as depression may show higher
predictive validity for AD in larger samples. Alter-
natively, the difference in findings could reflect a
complex difference between MCI patients referred
to clinics and the wider spectrum of cognitively im-
paired persons in the general community. Third, as
there are no specific recommended tools to diagnose
MCI, the operationalization of the criteria may
slightly differ from those in other studies. It is also
worth noting that prevalent cases of MCI were as-
sessed in the current study, which may include per-
sons with long-term cognitive impairment that
remains stable over time. In addition, the crude con-
version rates fromMCI to ADwere quite high in the
current study, possibly owing to the high age and
large proportion of females in the study population.
Therefore, we adjusted analyses for age, education,
and sex. Fourth, it is possible that that anxiety in the
elderly population, especially if measured with the
CPRS, is an indicator of some form of emotional
vulnerability, which could be a counterpart of mild
depression, or predepression symptoms. However,
we identified relevant categories of neuropsychiatric
symptoms based on previous research.14 Finally, our
results are based on an extremely old population
with a large proportion of women, and it could be
argued that the findings may differ from those in
younger elderly individuals. For example, vascular
disease is related to cognitive impairment, as well as
depressive symptoms,38 particularly motivation-
related symptoms.39 In this older population, vascu-
lar disease may be more prevalent and could
potentially affect the relationship between MCI and
depressive symptoms. However, another study
showed an increased risk of MCI due to depressive
symptoms is independent of underlying vascular
disease.13
The current study investigated longitudinally the
role of neuropsychiatric symptomatology in MCI in
the general population. Our findings suggest that
anxiety symptoms in MCI may represent a reaction
to the initial phases of cognitive deterioration. In
contrast, mood-related depressive symptoms could
be considered a preclinical sign of AD, and they
might be related to the neuropathologic mechanism.
The results also have clinical relevance, as they pro-
vide evidence for additional predictors for AD
within MCI, as well as in persons without cognitive
impairment. Psychiatric symptoms may increase
predictive ability and decrease the false-negative
rate in identifying future AD cases.
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